ARVINAS, INC.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 395 WINCHESTER AVE, NEW HAVEN, CT, 06511
Mailing Address 395 WINCHESTER AVE, NEW HAVEN, CT, 06511
Phone 203-535-1456
Fiscal Year End 1231
EIN 472566120
Financial Overview
FY2024
$660.00M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| 8-K Current report of material events | December 8, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | November 14, 2025 | View on SEC |
| 4 Insider stock transaction report | November 7, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 5, 2025 | View on SEC |
| 8-K Current report of material events | November 5, 2025 | View on SEC |
| 8-K Current report of material events | October 24, 2025 | View on SEC |
| 8-K Current report of material events | October 20, 2025 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | October 15, 2025 | View on SEC |
Material Events
8-K Leadership Change February 12, 2026
High Impact
- Dr. Randy Teel appointed new President and Chief Executive Officer, effective February 12, 2026.
- Dr. John Houston steps down from executive roles but will continue on the Board of Directors and as a consultant until March 2027.
Related Companies
Companies in the same industry (SIC: 2834)
Werewolf Therapeutics, Inc.
HOWL Pharmaceutical Preparations
Zenas BioPharma, Inc.
ZBIO Pharmaceutical Preparations
Centessa Pharmaceuticals plc
CNTA Pharmaceutical Preparations
Karyopharm Therapeutics Inc.
KPTI Pharmaceutical Preparations
VERTEX PHARMACEUTICALS INC / MA
VRTX Pharmaceutical Preparations
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.